CDC Warns Americans NOT to Get J&J Shot Over Blood Clot Risk

Share This:

(Remember what all the “crazy doctors” have been warning about….)

This article comes from “”

Update – A panel of health advisors to the Centers for Disease Control and Prevention voted Thursday unanimously that adults seeking boosters should go with Pfizer-BioNTech or Moderna vaccine rather than Johnson & Johnson vaccine.

The Advisory Committee on Immunization Practices voted 15-0 that the mRNA vaccines are “preferred” to the J&J vaccine because they’re the safest and most effective vaccines. 

CDC Director Rochelle Walensky is expected to decide whether to adopt the panel’s advice as agency policy later today. 

Johnson & Johnson’s COVID-19 vaccine has been linked to rare forms of blood clotting. 

A panel of experts who advise the Centers for Disease Control and Prevention (CDC) on vaccines is meeting Thursday to discuss updates to a severe condition linked to Johnson & Johnson’s COVID-19 vaccine.

The panel will listen to presentations by CDC officials on thrombosis with thrombocytopenia syndrome (TTS), which U.S. drug regulators say has a “causal relationship” with the jab, according to a draft agenda for the meeting.

The syndrome is a combination of blood clots and low blood platelet levels.

Concern over patients getting the syndrome after getting the vaccine led to a near-nationwide pause in administering the shot in the spring, but the pause was lifted after the Food and Drug Administration (FDA) determined the benefits of the vaccine outweighed its risks.

Since then, more evidence has emerged linking the syndrome to the vaccine.

Researchers with the CDC last month found people who got the Johnson & Johnson (J&J) shot were far more likely to experience the syndrome when compared to people who got a Moderna or Pfizer COVID-19 vaccine.

The reporting rate to the Vaccine Adverse Event Reporting System (VAERS), a system run by the CDC and the FDA, was 3.55 per million doses administered for the Johnson & Johnson vaccine, compared to 0.0057 per million doses administered after one of the other vaccines.

The rate was the highest among women aged 30 to 39.

Share This: